A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
An Open-label, 2-Period, 2-Sequence Cross-over Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin in Healthy Participants
Sponsor: AstraZeneca
Listed as NCT05787002, this PHASE1 trial focuses on Dyslipidemia and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — May 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE1
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .